Strategic Investment Advisors MI Trims Holdings in Danaher Co. (NYSE:DHR)

Strategic Investment Advisors MI lowered its holdings in Danaher Co. (NYSE:DHR) by 5.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,410 shares of the conglomerate’s stock after selling 89 shares during the quarter. Strategic Investment Advisors MI’s holdings in Danaher were worth $324,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Fort Pitt Capital Group LLC lifted its holdings in shares of Danaher by 3.2% in the 3rd quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after buying an additional 7,421 shares during the period. Good Life Advisors LLC acquired a new position in Danaher in the third quarter valued at approximately $217,000. ORG Partners LLC boosted its position in Danaher by 1,212.8% in the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after purchasing an additional 2,559 shares in the last quarter. Harvest Portfolios Group Inc. grew its stake in shares of Danaher by 1.2% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after purchasing an additional 2,465 shares during the period. Finally, Stifel Financial Corp lifted its stake in shares of Danaher by 1.3% in the 3rd quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after purchasing an additional 11,216 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on DHR. Robert W. Baird dropped their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Evercore ISI raised their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Citigroup reduced their price target on Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. Raymond James reduced their price target on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research report on Tuesday, January 21st. Finally, TD Cowen boosted their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Price Performance

Shares of DHR opened at $250.51 on Tuesday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a fifty-two week low of $225.42 and a fifty-two week high of $281.70. The company has a market cap of $180.94 billion, a P/E ratio of 47.81, a PEG ratio of 4.43 and a beta of 0.83. The firm’s 50 day moving average price is $235.33 and its 200 day moving average price is $253.62.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.